Dr. Mutch on Biomarkers in Endometrial Cancer

David Mutch, MD
Published: Tuesday, Feb 27, 2018



David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses molecular biomarkers in endometrial cancer.

There are currently no molecular markers for determining which treatment to give a patient with endometrial cancer, explains Mutch. The field has not had success in utilizing conventional marker such as lymphovascular space involvement, depth of invasion, grade of the tumor, or histologic type—whether it is papillary, serous, or clear cell.

However, there is molecular data from The Cancer Genome Atlas study showing that patients who have a POLE [polymerase epsilon] mutation—though they often have poorly differentiated tumors—almost never recur, says Mutch. If patients are routinely screened for POLE mutations, those patients do not need adjuvant therapy. By utilizing molecular characterizations, it is possible to eliminate many patients who might not need any additional therapy, Mutch explains.
 


David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses molecular biomarkers in endometrial cancer.

There are currently no molecular markers for determining which treatment to give a patient with endometrial cancer, explains Mutch. The field has not had success in utilizing conventional marker such as lymphovascular space involvement, depth of invasion, grade of the tumor, or histologic type—whether it is papillary, serous, or clear cell.

However, there is molecular data from The Cancer Genome Atlas study showing that patients who have a POLE [polymerase epsilon] mutation—though they often have poorly differentiated tumors—almost never recur, says Mutch. If patients are routinely screened for POLE mutations, those patients do not need adjuvant therapy. By utilizing molecular characterizations, it is possible to eliminate many patients who might not need any additional therapy, Mutch explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x